Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111449 | 1.00 | CYP3A4 (0.41) | CYP3A4CRBNSNCAJAK2JAK1 | |
| SCHEMBL2111414 | 0.87 | CYP3A4 (0.41) | CYP3A4SNCAJAK2JAK1TYK2 | |
| SCHEMBL2111413 | 0.87 | CYP3A4 (0.41) | CYP3A4SNCAJAK2JAK1TYK2 | |
| SCHEMBL1764553 | 0.80 | CRBN (0.59) | CRBNJAK2JAK1TYK2JAK3 | |
| SCHEMBL2512149 | 0.78 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL2512148 | 0.78 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL2745821 | 0.76 | CYP3A4 (0.43) | CYP3A4SNCA | |
| SCHEMBL2745819 | 0.76 | CYP3A4 (0.43) | CYP3A4SNCA | |
| SCHEMBL12769060 | 0.76 | CRBN (0.50) | CYP3A4CRBN | |
| SCHEMBL14647541 | 0.76 | CRBN (0.48) | CYP3A4CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445875-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | claimed |
| WO-2010149598-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| EP-2445875-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | disclosed |
| WO-2010149598-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885CRBN 2969/4885SNCA 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.